Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
32
AVDL Quote, Financials, Valuation and Earnings
Last price:
$10.12
Seasonality move
:
14.2%
Day range:
$9.98 - $10.53
52-week range:
$9.41 - $19.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.98x
P/B ratio:
13.31x
Volume:
1.2M
Avg. volume:
1.6M
1-year change:
-23.97%
Market cap:
$993.5M
Revenue:
$28M
EPS (TTM):
-$0.76
Analysts' Opinion
-
Consensus RatingAvadel Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Avadel Pharmaceuticals PLC has an estimated upside of 125.99% from its current price of $10.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $10.31.
Fair Value
-
According to the consensus of 0 analysts, Avadel Pharmaceuticals PLC has 125.99% upside to fair value with a price target of -- per share.
AVDL vs. S&P 500
-
Over the past 5 trading days, Avadel Pharmaceuticals PLC has overperformed the S&P 500 by 1.24% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Avadel Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avadel Pharmaceuticals PLC has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Avadel Pharmaceuticals PLC reported revenues of $50M.
Earnings Growth
-
Avadel Pharmaceuticals PLC earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avadel Pharmaceuticals PLC reported earnings per share of -$0.03.
Enterprise value:
927.7M
EV / Invested capital:
12.42x
Price / LTM sales:
6.98x
EV / EBIT:
--
EV / Revenue:
6.71x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-11.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$127M
Return On Assets:
-42.62%
Net Income Margin (TTM):
-52.53%
Return On Equity:
-86.15%
Return On Invested Capital:
-82.02%
Operating Margin:
-0.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $138.2M | $7M | $50M | |
| Gross Profit | -- | $8.4M | $127M | $6.9M | $43.9M | |
| Operating Income | -$95.1M | -$136.2M | -$64M | -$35.1M | -$327K | |
| EBITDA | -$96.4M | -$146.1M | -$60.5M | -$33.6M | $1.3M | |
| Diluted EPS | -$2.23 | -$2.16 | -$0.76 | -$0.41 | -$0.03 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $281.7M | $205.8M | $113.2M | $172.3M | $127.3M | |
| Total Assets | $327.6M | $264.1M | $145.8M | $203.1M | $158.3M | |
| Current Liabilities | $23M | $17.6M | $41.5M | $54.1M | $42.8M | |
| Total Liabilities | $156.4M | $165.1M | $158.2M | $93M | $83.6M | |
| Total Equity | $171.2M | $99M | -$12.4M | $110.1M | $74.7M | |
| Total Debt | $126.5M | $142.1M | $136.2M | $21.2M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$77.4M | -$115.8M | -$82.8M | -$38.2M | -$6.9M | |
| Cash From Investing | $72.1M | -$55.1M | $64.8M | $9.8M | $4.9M | |
| Cash From Financing | $7.9M | $163.1M | -$6M | $30.5M | $1.2M | |
| Free Cash Flow | -$78.2M | -$115.8M | -$82.8M | -$38.2M | -$6.9M | |
AVDL
Sector
Market Cap
$993.5M
$43.9M
Price % of 52-Week High
54.01%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-0.4%
-0.74%
1-Year Price Total Return
-23.97%
-29.11%
Beta (5-Year)
1.317
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$10.47
200-day SMA
Sell
Level
$14.82
Bollinger Bands (100)
Sell
Level
11.4 - 15.44
Chaikin Money Flow
Buy
Level
31.7M
20-day SMA
Sell
Level
$10.58
Relative Strength Index (RSI14)
Sell
Level
41.52
ADX Line
Sell
Level
12.32
Williams %R
Neutral
Level
-55.665
50-day SMA
Sell
Level
$12.22
MACD (12, 26)
Sell
Level
-0.53
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
141.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4074)
Sell
CA Score
(Annual)
Level (-6.233)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (6.6461)
--
Piotroski F Score
(Annual)
Level (--)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Stock Forecast FAQ
In the current month, AVDL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AVDL average analyst price target in the past 3 months is --.
-
Where Will Avadel Pharmaceuticals PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avadel Pharmaceuticals PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Avadel Pharmaceuticals PLC?
Analysts are divided on their view about Avadel Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avadel Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Avadel Pharmaceuticals PLC's Price Target?
The price target for Avadel Pharmaceuticals PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AVDL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avadel Pharmaceuticals PLC is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVDL?
You can purchase shares of Avadel Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avadel Pharmaceuticals PLC shares.
-
What Is The Avadel Pharmaceuticals PLC Share Price Today?
Avadel Pharmaceuticals PLC was last trading at $10.12 per share. This represents the most recent stock quote for Avadel Pharmaceuticals PLC. Yesterday, Avadel Pharmaceuticals PLC closed at $10.31 per share.
-
How To Buy Avadel Pharmaceuticals PLC Stock Online?
In order to purchase Avadel Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
